![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RAB18 |
Gene summary for RAB18 |
![]() |
Gene information | Species | Human | Gene symbol | RAB18 | Gene ID | 22931 |
Gene name | RAB18, member RAS oncogene family | |
Gene Alias | RAB18LI1 | |
Cytomap | 10p12.1 | |
Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q9NP72 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22931 | RAB18 | LZE4T | Human | Esophagus | ESCC | 1.14e-24 | 1.21e+00 | 0.0811 |
22931 | RAB18 | LZE7T | Human | Esophagus | ESCC | 6.57e-07 | 1.95e-01 | 0.0667 |
22931 | RAB18 | LZE8T | Human | Esophagus | ESCC | 2.87e-04 | 3.12e-01 | 0.067 |
22931 | RAB18 | LZE20T | Human | Esophagus | ESCC | 3.58e-06 | 2.13e-01 | 0.0662 |
22931 | RAB18 | LZE22T | Human | Esophagus | ESCC | 1.56e-04 | 2.75e-01 | 0.068 |
22931 | RAB18 | LZE24T | Human | Esophagus | ESCC | 4.28e-13 | 7.29e-01 | 0.0596 |
22931 | RAB18 | LZE21T | Human | Esophagus | ESCC | 6.04e-03 | 3.54e-01 | 0.0655 |
22931 | RAB18 | LZE6T | Human | Esophagus | ESCC | 3.89e-03 | 1.23e-01 | 0.0845 |
22931 | RAB18 | P1T-E | Human | Esophagus | ESCC | 3.18e-04 | 3.01e-01 | 0.0875 |
22931 | RAB18 | P2T-E | Human | Esophagus | ESCC | 1.85e-33 | 4.25e-01 | 0.1177 |
22931 | RAB18 | P4T-E | Human | Esophagus | ESCC | 1.56e-15 | 6.75e-01 | 0.1323 |
22931 | RAB18 | P5T-E | Human | Esophagus | ESCC | 1.45e-30 | 6.12e-01 | 0.1327 |
22931 | RAB18 | P8T-E | Human | Esophagus | ESCC | 9.74e-26 | 3.87e-01 | 0.0889 |
22931 | RAB18 | P9T-E | Human | Esophagus | ESCC | 2.22e-23 | 7.43e-01 | 0.1131 |
22931 | RAB18 | P10T-E | Human | Esophagus | ESCC | 1.02e-29 | 5.43e-01 | 0.116 |
22931 | RAB18 | P11T-E | Human | Esophagus | ESCC | 2.20e-20 | 1.18e+00 | 0.1426 |
22931 | RAB18 | P12T-E | Human | Esophagus | ESCC | 1.03e-51 | 1.04e+00 | 0.1122 |
22931 | RAB18 | P15T-E | Human | Esophagus | ESCC | 8.60e-31 | 8.37e-01 | 0.1149 |
22931 | RAB18 | P16T-E | Human | Esophagus | ESCC | 4.00e-32 | 5.97e-01 | 0.1153 |
22931 | RAB18 | P17T-E | Human | Esophagus | ESCC | 3.81e-04 | 5.79e-01 | 0.1278 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000702914 | Esophagus | ESCC | endoplasmic reticulum organization | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
GO:00717865 | Esophagus | ESCC | endoplasmic reticulum tubular network organization | 15/8552 | 18/18723 | 1.20e-03 | 5.88e-03 | 15 |
GO:00070292 | Liver | Cirrhotic | endoplasmic reticulum organization | 42/4634 | 87/18723 | 1.67e-06 | 3.22e-05 | 42 |
GO:00717861 | Liver | Cirrhotic | endoplasmic reticulum tubular network organization | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:000702911 | Liver | HCC | endoplasmic reticulum organization | 64/7958 | 87/18723 | 3.92e-09 | 1.04e-07 | 64 |
GO:00717862 | Liver | HCC | endoplasmic reticulum tubular network organization | 15/7958 | 18/18723 | 4.74e-04 | 3.12e-03 | 15 |
GO:00070294 | Oral cavity | OSCC | endoplasmic reticulum organization | 58/7305 | 87/18723 | 1.59e-07 | 2.61e-06 | 58 |
GO:00717864 | Oral cavity | OSCC | endoplasmic reticulum tubular network organization | 14/7305 | 18/18723 | 9.51e-04 | 4.96e-03 | 14 |
GO:000702913 | Oral cavity | LP | endoplasmic reticulum organization | 41/4623 | 87/18723 | 4.49e-06 | 9.16e-05 | 41 |
GO:007178611 | Oral cavity | LP | endoplasmic reticulum tubular network organization | 10/4623 | 18/18723 | 4.91e-03 | 3.06e-02 | 10 |
GO:00070293 | Prostate | BPH | endoplasmic reticulum organization | 26/3107 | 87/18723 | 1.45e-03 | 8.61e-03 | 26 |
GO:000702912 | Prostate | Tumor | endoplasmic reticulum organization | 27/3246 | 87/18723 | 1.24e-03 | 7.83e-03 | 27 |
GO:00016541 | Prostate | Tumor | eye development | 82/3246 | 371/18723 | 1.02e-02 | 4.27e-02 | 82 |
GO:00717866 | Skin | AK | endoplasmic reticulum tubular network organization | 6/1910 | 18/18723 | 7.04e-03 | 3.63e-02 | 6 |
GO:00070296 | Skin | cSCC | endoplasmic reticulum organization | 42/4864 | 87/18723 | 6.36e-06 | 8.92e-05 | 42 |
GO:007178612 | Skin | cSCC | endoplasmic reticulum tubular network organization | 11/4864 | 18/18723 | 1.74e-03 | 1.06e-02 | 11 |
GO:00717867 | Thyroid | HT | endoplasmic reticulum tubular network organization | 6/1272 | 18/18723 | 8.86e-04 | 9.30e-03 | 6 |
GO:00070297 | Thyroid | HT | endoplasmic reticulum organization | 13/1272 | 87/18723 | 5.73e-03 | 3.72e-02 | 13 |
GO:000702915 | Thyroid | PTC | endoplasmic reticulum organization | 51/5968 | 87/18723 | 2.37e-07 | 4.15e-06 | 51 |
GO:007178613 | Thyroid | PTC | endoplasmic reticulum tubular network organization | 14/5968 | 18/18723 | 8.31e-05 | 7.01e-04 | 14 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RAB18 | SNV | Missense_Mutation | c.95N>G | p.Thr32Arg | p.T32R | Q9NP72 | protein_coding | deleterious(0.03) | benign(0.086) | TCGA-E9-A247-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
RAB18 | SNV | Missense_Mutation | c.158A>G | p.Asp53Gly | p.D53G | Q9NP72 | protein_coding | tolerated(0.41) | benign(0.139) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
RAB18 | SNV | Missense_Mutation | novel | c.455N>G | p.Lys152Arg | p.K152R | Q9NP72 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
RAB18 | SNV | Missense_Mutation | novel | c.370N>G | p.Thr124Ala | p.T124A | Q9NP72 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RAB18 | SNV | Missense_Mutation | novel | c.503T>G | p.Phe168Cys | p.F168C | Q9NP72 | protein_coding | deleterious(0.01) | benign(0.33) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB18 | SNV | Missense_Mutation | novel | c.167N>C | p.Lys56Thr | p.K56T | Q9NP72 | protein_coding | tolerated(0.15) | benign(0.023) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
RAB18 | SNV | Missense_Mutation | novel | c.605N>A | p.Pro202His | p.P202H | Q9NP72 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
RAB18 | SNV | Missense_Mutation | rs140686479 | c.472C>T | p.Arg158Cys | p.R158C | Q9NP72 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
RAB18 | SNV | Missense_Mutation | novel | c.467N>G | p.Glu156Gly | p.E156G | Q9NP72 | protein_coding | deleterious(0.02) | benign(0.232) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RAB18 | SNV | Missense_Mutation | novel | c.281N>A | p.Ala94Asp | p.A94D | Q9NP72 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |